Publications by authors named "Antonina V Artemeva"
Article Synopsis
- The study aimed to compare the effectiveness, safety, and pharmacokinetics of BCD-057 with the well-known drug adalimumab (iADA) for treating moderate to severe plaque psoriasis.
- A total of 346 patients participated, with 60% of BCD-057 users achieving significant improvement at week 16, showing both drugs are similarly effective over time.
- Both treatments exhibited comparable safety profiles, and switching from iADA to BCD-057 did not impact the patients' immune response, confirming their similarity.
Efficacy and Safety of Netakimab, A Novel Anti-IL-17 Monoclonal Antibody, in Patients with Moderate to Severe Plaque Psoriasis. Results of A 54-Week Randomized Double-Blind Placebo-Controlled PLANETA Clinical Trial.
Luís Puig Andrey L Bakulev Muza M Kokhan Alexey V Samtsov Vladislav R Khairutdinov Antonina V Artemeva
Dermatol Ther (Heidelb)
August 2021
Introduction: Netakimab (NTK), an original humanized anti-interleukin-17 monoclonal antibody, showed therapeutic efficacy in moderate-to-severe plaque psoriasis in a phase 2 clinical study. Herein we report the results of 54 weeks of a phase 3 PLANETA trial aimed to evaluate the efficacy and safety of two NTK regimens vs. placebo.
View Article and Find Full Text PDF